Statement Of Cash Flows [Abstract]

BerGenBio - Filing #5877180

Concept	2024-01-01 to 2024-12-31	As at 2024-12-31	2024-01-01 to 2024-12-31	2023-01-01 to 2023-12-31	As at 2023-12-31	2023-01-01 to 2023-12-31	As at 2022-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)	139,282,000 NOK	—	139,282,000 NOK	190,401,000 NOK	—	190,401,000 NOK	—
Adjustments to reconcile profit (loss) [abstract]
Adjustments for provisions	42,000 NOK	—	—	42,000 NOK	—	—	—
Adjustments for unrealised foreign exchange losses (gains)	4,927,000 NOK	—	—	1,613,000 NOK	—	—	—
Adjustments for share-based payments	5,709,000 NOK	—	—	3,135,000 NOK	—	—	—
Cash flows from (used in) operating activities	153,242,000 NOK	—	—	225,101,000 NOK	—	—	—
Cash flows from (used in) investing activities [abstract]
Proceeds from sales of property, plant and equipment, classified as investing activities	167,000 NOK	—	—	0 NOK	—	—	—
Interest received, classified as investing activities	3,521,000 NOK	—	—	3,055,000 NOK	—	—	—
Cash flows from (used in) investing activities	3,688,000 NOK	—	—	3,055,000 NOK	—	—	—
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares	138,874,000 NOK	—	—	262,048,000 NOK	—	—	—
Payments of lease liabilities, classified as financing activities	438,000 NOK	—	—	193,000 NOK	—	—	—
Cash flows from (used in) financing activities	129,609,000 NOK	—	—	224,884,000 NOK	—	—	—
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes	19,945,000 NOK	—	—	2,838,000 NOK	—	—	—
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents	3,678,000 NOK	—	—	2,780,000 NOK	—	—	—
Cash and cash equivalents	—	140,155,000 NOK	—	—	156,421,000 NOK	—	150,803,000 NOK